Trial Profile
A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of Nolasiban to Increase On-going Pregnancy Rate Following Fresh Single Blastocyst Transfer Resulting From IVF
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2021
Price :
$35
*
At a glance
- Drugs Nolasiban (Primary)
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms IMPLANT 4
- Sponsors ObsEva
- 08 Sep 2021 Status changed from active, no longer recruiting to completed.
- 04 Aug 2021 Results published in an ObsEva Media Release.
- 04 Aug 2021 According to an ObsEva media release, results of meta-analysis of three studies (IMPLANT, IMPLANT2 & IMPLANT 4) assessing pregnancy rate in the nolasiban 900 mg vs placebo groups, published in the Journal of Human Reproduction.